For CROs
ArtFun+ provides clinically-validated imaging biomarkers that help CROs to optimize the process of Evaluating Drug Therapeutic Efficacy
Enhance clinical trial success with imaging biomarkers
ArtFun+‘s imaging biomarkers offer the opportunity for CROs to improve the evaluation of therapeutic efficacy in cardiovascular clinical trials and facilitate market access. Our arterial stiffness and flow biomarkers have the capacity to provide reliable clinical insights into how a drug influences cardiovascular health, and it’s potential effectiveness, whether in hypertension trials, atherosclerosis, or broader cardiovascular indications.
By using ArtFun+ imaging biomarkers, CROs can measure the therapeutic response over time, reducing patient risk and discomfort while increasing the accuracy of the assessment.
Enables safe monitoring of clinical trials with confidence
Artfun+ technology was endorsed by more than 77 publications in 13 countries and empowered the understanding of CV diseases – indicating a trusted method by world-class journals
Faster go/no-go decisions in drug development
Artfun+ imaging biomarkers can Mitigate risks of adverse events in clinical trials and enhance R&D strategy.
Influence regulatory authorities and investors
Demonstrate safety, quality and efficacy of drug candidate with novel precision imaging biomarkers
Let’s Empower Clinical Trials
in growing therapeutic areas